Clinical Trial Update: SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating SHR1020 plus docetaxel versus placebo plus docetaxel in second-line non-squamous non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• SHR1020

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Non Squamous Non Small Cell Lung | Phase 3 | Status: TERMINATED